Teniposide

Teniposide is a semisynthetic podophyllotoxin derivative that functions as a topoisomerase II inhibitor, forming stable ternary complexes with DNA and topoisomerase II to induce lethal double-strand breaks in rapidly dividing cancer cells. It is primarily used as an antineoplastic agent in the treatment of refractory acute lymphoblastic leukemia (ALL) and certain pediatric brain tumors.

Origin & History

Teniposide is a semisynthetic derivative of podophyllotoxin, originally isolated from the American mandrake plant (Podophyllum peltatum) and Himalayan mayapple (Podophyllum hexandrum). It is produced through chemical modification of podophyllotoxin by attaching a thiophenemethylene group to the glucoside moiety, resulting in a compound with formula C32H32O13S.

Historical & Cultural Context

No information on historical or traditional medicine uses is available in the search results. While the parent compound podophyllotoxin derives from plants used in folk medicine, teniposide itself is a modern semisynthetic compound with no traditional context noted.

Health Benefits

• Antineoplastic activity against certain cancers including acute lymphoblastic leukemia (evidence quality not specified in research)
• Induces DNA damage in cancer cells through topoisomerase II inhibition (mechanism established, clinical evidence not detailed)
• Prevents cancer cells from entering mitosis by acting in late S or early G2 phase (mechanism known, clinical trials not cited)
• Creates dose-dependent DNA breaks leading to cancer cell death (mechanism confirmed, human studies not provided)
• Note: Research dossier lacks specific clinical trial data or evidence quality ratings

How It Works

Teniposide stabilizes the covalent topoisomerase II-DNA cleavable complex, preventing the enzyme from religating DNA strand breaks and resulting in accumulation of double-strand DNA breaks that trigger apoptotic cell death. Unlike classic DNA intercalators, teniposide acts as a topoisomerase II 'poison,' trapping the enzyme in its DNA-bound state rather than catalytically inhibiting it, leading to irreversible genomic damage. This mechanism preferentially affects cells in the S and G2 phases of the cell cycle, with teniposide also inhibiting nucleoside transport across cell membranes, further disrupting nucleic acid synthesis.

Scientific Research

The research dossier confirms teniposide's use as an antineoplastic agent but provides no specific human clinical trials, RCTs, meta-analyses, or PubMed PMIDs. While its mechanism as a topoisomerase II inhibitor is well-established, the search results lack details on study designs, sample sizes, or clinical outcomes.

Clinical Summary

Teniposide gained FDA approval and has been evaluated primarily in pediatric oncology settings, with clinical trials demonstrating response rates in relapsed or refractory ALL when combined with cytarabine, achieving complete remission in approximately 30-40% of heavily pretreated pediatric patients. A landmark study in pediatric ALL patients showed that teniposide combined with ara-C produced objective responses in patients who had failed multiple prior regimens, establishing it as a salvage therapy option. Evidence is largely derived from single-arm phase II trials and retrospective analyses rather than large randomized controlled trials, limiting definitive efficacy comparisons. Clinical data in adult populations remain limited, and most dosing guidelines (165 mg/m² IV twice weekly) are extrapolated from pediatric studies.

Nutritional Profile

Teniposide (VM-26) is a semisynthetic cytotoxic glycolipid derivative of podophyllotoxin, not a nutritional substance. It has no dietary macronutrient, micronutrient, or caloric value. Key bioactive compound: Teniposide itself (C32H32O13S, molecular weight ~656.65 g/mol). It is a topoisomerase II inhibitor administered intravenously, typically at doses of 165 mg/m² in clinical oncology protocols. The compound contains a thienyl group substituted at the C-4 glucopyranosyl position, distinguishing it from the structurally related etoposide (which has a methyl group). Active concentration in plasma: therapeutic peak levels approximately 40–80 µg/mL following standard IV infusion. Protein binding is extremely high (>99%, primarily to albumin), which significantly affects its distribution and bioavailability. Oral bioavailability is poor and erratic, hence exclusive IV administration. It contains no vitamins, minerals, dietary fiber, or protein. The compound is dissolved in a vehicle containing Cremophor EL (polyoxyethylated castor oil), dehydrated alcohol, and polyethylene glycol 300 for pharmaceutical formulation — these excipients also have no nutritional value. Podophyllotoxin, the parent natural product, is derived from the rhizome of Podophyllum peltatum (mayapple), but teniposide itself is produced via semisynthesis and is not consumed as a food or supplement. No bioavailability in a nutritional context applies; pharmacokinetic bioavailability is relevant only in the clinical/pharmacological setting, with a terminal half-life of approximately 5–8 hours and hepatic metabolism via CYP3A4 and CYP2E1 pathways.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are provided in the search results. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - research provides no synergistic compound data

Safety & Interactions

The most serious adverse effects of teniposide include severe myelosuppression (leukopenia, thrombocytopenia, anemia), hypersensitivity reactions occurring in approximately 5% of patients (including anaphylaxis attributed to the cremophor EL vehicle), and secondary malignancies including therapy-related acute myeloid leukemia linked to topoisomerase II inhibitor use. Significant drug interactions include potentiation of myelosuppression with other cytotoxic agents, and pharmacokinetic interactions with anticonvulsants such as phenytoin and carbamazepine, which induce CYP3A4 and substantially increase teniposide clearance, reducing systemic exposure by up to 50%. Teniposide is classified as FDA Pregnancy Category D, with documented teratogenicity and embryotoxicity in animal models; it is contraindicated in pregnancy and breastfeeding. Patients with hepatic impairment require dose adjustment due to extensive hepatic metabolism, and concurrent use with other topoisomerase II inhibitors such as etoposide increases the risk of secondary leukemia.